This is a double blind, placebo-controlled clinical trial of ultra-high CBD, hemp-derived study product in patients with newly diagnosed with Gioblastoma (GBM).
This clinical trial will examine the effects of combining THC and cannabigerol on pain and other outcomes.
This is a preclinical study to investigate antinociceptive effects of THC, CBD, and a combination of THC and CBD on sickle cell disease.
The development of novel and more effective medications for alcohol use disorder (AUD) is a pressing medical need. Preclinical studies showed that chronic cannabidiol (CBD) treatment decreased alcohol drinking and prevented the reinstatement of alcohol seeking that was induced by environmental cues and stress.
This study will explore how prenatal exposure to CBD and other cannabinoids affects fetal development.
This project will combine a clinical observational study with two preclinical models to investigate whether cannabis can protect people with HIV from blood-brain-barrier damage by reducing inflammation and promoting mitochondrial homeostasis.
This is a clinical study looking at the intersection of cannabis, HIV, and the Central Nervous System.
This study will examine the effects of chronic cannabis use and the role of the endocannabinoid system on persistent inflammation in people with HIV.
This is a preclinical study to investigate genetic susceptibility to adverse and/or beneficial effects on anxiety of acute cannabinoid exposure.
This clinical trial will explore the effectiveness of cannabidiol (CBD), in reducing symptoms and improving cognition in early psychosis. Additionally, this trial will examine the effect of CBD on the biological response to stress, and the effect of CBD on eating behavior induced by antipsychotic medication.
This study will examine the microbiome and endocannabinoid system in people with HIV and how they relate to neuroinflamation and the blood-brain-barrier.
This is a clinical study to determine the effect of CBD on anxiety disorders.
This is a clinical study to evaluate the efficacy of cannabidiol in reducing cigarette smoking.
This study will explore CBD as a perioperative analgesic for orthopaedic pain.
This study will examine the impact of cannabis exposure on gut barrier function in metabolic disease and experimental colitis
This study will investigate whether terpenes have analgesic potential and whether they enhance endocannabinoid concentrations in the brain
This study aims to determine the influence of sex differences on CBD’s effects on cardiovascular functions.
This is a preclinical study to investigate whether terpenes can modulate both sensory and affective dimensions of ongoing chronic pain.
This is a clinical study to determine if vaporized cannabis directly reduces evoked chronic low back pain.
This clinical trial is examining if and how cannabidiol (CBD), a chemical found in the cannabis plant, provides therapeutic benefit to children with severe autism spectrum disorder (ASD). The trial is funded by a grant from the Ray and Tye Noorda Foundation in partnership with and based on recommendations from the Wholistic Research and Education Foundation.
This study will seek to determine the effects of THC use on glucose metabolism
Because there are no proven treatments that normalize core symptoms in adult anorexia nervosa (AN), a disorder with high chronicity and mortality, many individuals seek out alternative approaches to care. Recent evidence has suggested that exaggerated anxiety and diminished reward or motivation to eat play a key role in causing AN symptoms and poor outcome.
This study will examine whether CBD will reduce alexithymia and inflammation in people with HIV
This study will examine the effects of cannabis and cannabinoids on the behavioral and molecular outcomes of motivational and stress-mediated changes associated with prescription oxycodone addiction and dependence.
The overall goal of this proof-of-principle proposal is to examine the efficacy and safety of CBD treatment as adjunctive to the medical management of Rheumatoid Arthritis (RA) patients with moderate to severe disease activity.
This study will utilize a cross-species approach to delineate the effects EC system activation has on HIV-relevant cognitive and motivational domains.
